

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/518,206	12/16/2004	Pingyun Y. Chen	P51364	3204
20462	7590 07/13/2006		EXAMINER	
SMITHKLINE BEECHAM CORPORATION			AULAKH, CHARANJIT	
P. O. BOX 1	RATE INTELLECTUAL PROPERTY-US, UW2220 DX 1539		ART UNIT	PAPER NUMBER
KING OF PF	JSSIA, PA 19406-0939		1625	
			DATE MAILED: 07/13/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/518,206	CHEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Charanjit S. Aulakh	1625				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from to, cause the application to become ABANDONED	l. ely filed he mailing date of this communication. O (35 U.S.C. § 133).				
Status						
 Responsive to communication(s) filed on <u>07 Ai</u> This action is FINAL. Since this application is in condition for allowar closed in accordance with the practice under Eight 	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4) Claim(s) 1-40 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1-40 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction in the original sheet are considered to by the Examine sheet are considered to be considered to by the Examine sheet are considered to be considered t	wn from consideration. r election requirement. r. epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obje	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicationity documents have been received (PCT Rule 17.2(a)).	n No d in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 4/7/06 and 1/30/06.	4) Interview Summary (Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	e				

Application/Control Number: 10/518,206

Art Unit: 1625

DETAILED ACTION

Page 2

1. According to paper filed on April 7, 2006, the applicants have amended claim 1.

2. Claims 1-40 are pending in the application.

Response to Arguments

3. Applicant's arguments filed on April 7, 2006 have been fully considered but they are not persuasive regarding prior art rejections as well as regarding obviousness rejections. In regard to prior art rejection, the examiner does not agree with the applicants arguments that the examiner did not set forth a prima facie basis for the statement that instant hydrate and anhydrous forms will not be maintained in pharmaceutical composition as well as following in vivo administration. The utility of treating hypertension and angina pectoris using instant hydrate and anhydrous forms of carvedilol is identical to the utility of free base form of carvedilol disclosed by Wiedemann. The utility of carvedilol is due to the compound itself and not due to hydrate or anhydrous form. The applicants did not provide any evidence that hydrate form and anhydrous form of carvedilol will be maintained in pharmaceutical composition or following in vivo administration.

In regard to obviousness rejection, the examiner does not agree with the applicants arguments that Hildesheim does not provide any motivation to one skilled in the art to prepare the instant carvedilol hydrobromide hydrate, salt, solvate or anhydrate. The applicants admit that Hildesheim teaches preparing carvedilol hydrochloride hydrate form (see page 9, last three lines). The only difference between the instant compounds and the compounds of Hildesheim is the salt. As stated clearly in the last

Art Unit: 1625

office action, Hildesheim teaches the advantages of polymorphs, hydrates and solvates such as solubility in aquous solution, the ease of processing the form into pharmaceutical dosages etc. and therefore, provides the motivation to prepare different crystalline hydrate and solvate forms of carvedilol.

Conclusion

- 4. Rejection of claims 35-40 under 35 U.S.C. 102(b) is maintained for the reasons of record.
- 5. Rejection of claims 1-40 under 35 U.S.C. 103(a) is maintained for the reasons of record.
- 6. The provisional ODP rejection of claims 1-40 is maintained for the reasons of record.
- 7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is

Application/Control Number: 10/518,206 Page 4

Art Unit: 1625

(571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thomas McKenzie can be reached on (571)272-0670. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Charanjit S. Aulakh Primary Examiner Art Unit 1625